Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;27(10):3749-3758.
doi: 10.1007/s00520-019-04672-w. Epub 2019 Feb 1.

Cost-utility analysis of aprepitant for patients who truly need it in Japan

Ikuto Tsukiyama  1   2 , Masahiko Ando  3 , Sumiyo Tsukiyama  2 , Masayuki Takeuchi  2 , Masayuki Ejiri  2 , Yusuke Kurose  2 , Hiroko Saito  2 , Ichiro Arakawa  4 , Tadao Inoue  5 , Etsuro Yamaguchi  6 , Akihito Kubo  7
Affiliations

Cost-utility analysis of aprepitant for patients who truly need it in Japan

Ikuto Tsukiyama et al. Support Care Cancer. 2019 Oct.

Abstract

Purpose: Neurokinin-1 receptor antagonist (NK1RA) is recommended to prevent chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly or moderately emetogenic chemotherapy (HEC or MEC, respectively). We previously reported that aprepitant, an NK1RA, was needed to control CINV in 43% and 12% of patients who received HEC and MEC, respectively (Support Care Cancer 23:905-912, 2015). To elucidate the cost-effectiveness of aprepitant in these patients, a cost-utility analysis according to the necessity of aprepitant was performed.

Methods: A decision-analytic model was developed according to the necessity of aprepitant and CINV responses in both acute and delayed phases of chemotherapy. Probabilities of health states and medical costs were derived from the results of the abovementioned trial.

Result: In patients who received HEC and needed aprepitant, the incremental cost-effectiveness ratio (ICER) with aprepitant, relative to the regimen with no aprepitant, was 7912 US dollars (USD) per quality-adjusted life year (QALY) gained, which was far below the commonly accepted threshold of 50,000 USD/QALY. The ICER was 27,457 USD/QALY in patients who received MEC and needed aprepitant. In contrast, in patients who received HEC or MEC but did not need aprepitant, the ICER was 175,959 or 478,844 USD/QALY, respectively.

Conclusion: Regardless of whether a patient received HEC or MEC, aprepitant use was highly cost-effective for patients who truly needed it. These results warrant further research to predict the necessity of NK1RA treatment before initiating emetogenic chemotherapies.

Keywords: Aprepitant; Cost-effectiveness; Highly emetogenic chemotherapy (HEC); Incremental cost-effectiveness ratio (ICER); Moderately emetogenic chemotherapy (MEC); Neurokinin-1 receptor antagonist (NK1RA).

PubMed Disclaimer

References

    1. Herrstedt J (2002) Nausea and emesis: still an unsolved problem in cancer patients? Support Care Cancer 10(2):85–87. https://doi.org/10.1007/s00520-001-0339-7 - DOI - PubMed
    1. Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Langstrom B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55(10):1007–1012. https://doi.org/10.1016/j.biopsych.2004.02.007 - DOI - PubMed
    1. Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64(7):777–794 - DOI - PubMed
    1. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119. https://doi.org/10.1200/JCO.2003.01.095 - DOI - PubMed
    1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098. https://doi.org/10.1002/cncr.11433 - DOI - PubMed

MeSH terms

LinkOut - more resources